InvestorsHub Logo
Followers 4
Posts 1196
Boards Moderated 0
Alias Born 10/03/2015

Re: jondoeuk post# 15

Sunday, 08/28/2022 8:06:20 PM

Sunday, August 28, 2022 8:06:20 PM

Post# of 42
Looking at P1 data from Fate and NKTX, NK cells seem to be effective on indolent lymphoma and nodal DLBCL. For pts with high tumor burden or aggressive disease, CART will still be needed. I listened to NKTX presentation, the number of cycles given to a patient will be up to the oncologist.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPSC News